MedPath

Phase II Clinical Trial of Carbon-Ion Radiotherapy with Longer Hormone Therapy for Clinical Stage T1b-T3N0M0 Prostate Cancer

Phase 2
Conditions
ocalized prostate cancer
Registration Number
JPRN-UMIN000021517
Lead Sponsor
Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization
Brief Summary

This study confirmed safety and efficacy comparable to those reported from prior facilities.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patient with past history of radiotherapy for the targeted lesion 2) Patient with active double cancer 3) Patient with hormone-resistant prostate cancer 4) Patients with active and intractable infection in the targeted lesion 5) Patient with metal devices in the lesion 6) Other medical or psychological condition which is unsuitable for carbon-ion therapy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Biochemical progression-free survival at 5 years
Secondary Outcome Measures
NameTimeMethod
1) Overall survival, Disease-specific survival 2) Local recurrence-free survival 3) Early and late-phase adverse event rate
© Copyright 2025. All Rights Reserved by MedPath